Beyond Air Inc Stock Price, News & Analysis

Beyond Air (NASDAQ: XAIR) reported fiscal Q2 2026 results for the quarter ended September 30, 2025 with revenue +128% YoY to $1.8M and an updated fiscal 2026 revenue guidance of $8–$10M. The company closed a financing providing a $12.0M promissory note plus an equity line up to $20M, yielding a proforma cash balance of $22.9M and runway into calendar 2027. Net loss was $7.9M (–$1.25 per share), net cash burn was $4.7M for the quarter, and reported cash and marketable securities were $10.7M with long-term debt of $10.1M. Commercially, LungFit PH expanded to 35 countries, MDSAP certification was achieved, and a PMA supplement for second-generation LungFit PH was submitted in June 2025. Bob Goodman named interim Chief Commercial Officer.

Beyond Air (NASDAQ: XAIR) entered financing agreements with Streeterville Capital providing up to $32 million in potential proceeds: a $12 million promissory note and a $20 million equity line of credit (ELOC). Pro forma cash, cash equivalents, restricted cash and marketable securities totaled $22.9 million as of September 30, 2025, which includes the $12 million note. The promissory note bears 15% annual interest, matures in 24 months with no payments for the first 12 months, and places $6 million in a restricted account. The ELOC allows sale of up to $20 million of common stock over 24 months and requires an S-1 resale registration. Management says the financing extends runway into calendar 2027 and supports LungFit PH commercial expansion and a planned second-generation launch before end of 2026.

Beyond Air (NASDAQ: XAIR) will release second fiscal quarter 2026 financial results for the period ended September 30, 2025 on Monday, November 10, 2025. The company's management will host a conference call and webcast the same day at 4:30 PM Eastern Time to discuss results.

Dial-in details: Domestic 1-877-407-0784, International 1-201-689-8560, Conference ID 13756730. A live webcast will be available in the Events section of the company's website, and an online replay will be posted about one hour after the call.

Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025, in New York, NY.

The company's Chief Financial Officer, Douglas Larson, will be available for one-on-one meetings with investors during the conference. Interested investors can schedule meetings through their Roth Capital Partners representatives.

Beyond Air (NASDAQ: XAIR) has secured approximately $3.25 million in gross proceeds through the exercise of existing warrants. The agreement involves the immediate exercise of warrants to purchase 1,439,126 shares of common stock at a reduced price of $2.21 per share.

As part of the transaction, the company will issue new unregistered warrants to purchase up to 719,561 shares of common stock at $0.0625 per warrant. These new warrants will have an exercise price of $2.21 per share, with immediate exercisability and a five-year term. The proceeds will support Beyond Air's clinical and pre-clinical programs, operating expenses, and working capital.

NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has received FDA Orphan Drug Designation (ODD) for its lead therapy BA-101 in treating Glioblastoma (GBM), an aggressive brain cancer. This marks the company's second ODD and its entry into oncology.

GBM currently has limited treatment options with median survival less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years. The ODD grants several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers.

The company's approach focuses on NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response.

Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.

Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.

Beyond Air (NASDAQ: XAIR) has expanded its global distribution network for LungFit PH, a medical device that generates nitric oxide from ambient air. The company has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, bringing its total international coverage to 34 countries with a combined population of 2.7 billion people.

In Japan, Beyond Air partnered with AMCO Incorporated, a leading medical device distributor with over 70 years of experience. The LungFit PH system eliminates the need for traditional high-pressure cylinders, offering a more efficient and environmentally friendly solution for hospital settings. Hospital tender submissions are currently in progress in several regions while awaiting regulatory approvals in others.

Beyond Air (NASDAQ: XAIR) reported strong fiscal Q1 2026 results, with revenue surging 157% to $1.8 million compared to $0.7 million in the same period last year. The company secured a significant national group purchasing agreement with Premier, Inc., gaining access to over 4,350 member hospitals and health systems.

The company reaffirmed its FY2026 revenue guidance of $12-16 million. LungFit PH's commercial expansion continues globally, now reaching over 30 countries. Beyond Air reported a net loss of $7.7 million ($1.53 per share) and cash position of $6.5 million as of June 30, 2025. The company recently completed a 1-for-20 reverse stock split to maintain Nasdaq compliance.